Cost-Effectiveness of PDL1 Based Test-And-Treat Strategy with Pembrolizumab as the 1st Line Treatment for NSCLC in Hong Kong

被引：0
|
作者：
Loong, H. [1 ]
Huang, M. [2 ]
Wong, C. [3 ]
Leung, L. [1 ]
Burke, T. [4 ]
Chandwani, S. [4 ]
Law, A. [5 ]
Tan, S. C. [6 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Merck & Co Inc, Ctr Observat & Real World Evidence, N Wales, PA USA
[3] Univ Hong Kong, Dept Family Med & Primary Care, Hong Kong, Peoples R China
[4] Merck & Co Inc, Ctr Observat & Real World Evidence, Rahway, NJ 07065 USA
[5] Merck Sharp & Dohme Ltd, Hong Kong, Peoples R China
[6] Merck Sharp & Dohme Asia Pacific, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
cost effectiveness; BTS in Hong Kong; pembrolizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-050
引用
收藏
页码：S1912 / S1912
页数：1
相关论文
共 50 条
  • [1] Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
    Herbert H. Loong
    Carlos K. H. Wong
    Linda Kam Suet Leung
    Praveen Dhankhar
    Ralph P. Insinga
    Sheenu Chandwani
    Danny C. Hsu
    Mary Y. K. Lee
    Min Huang
    James Pellissier
    Akanksha Rai
    Monika Achra
    Seng Chuen Tan
    PharmacoEconomics - Open, 2020, 4 : 235 - 247
  • [2] Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
    Loong, Herbert H.
    Wong, Carlos K. H.
    Leung, Linda Kam Suet
    Dhankhar, Praveen
    Insinga, Ralph P.
    Chandwani, Sheenu
    Hsu, Danny C.
    Lee, Mary Y. K.
    Huang, Min
    Pellissier, James
    Rai, Akanksha
    Achra, Monika
    Tan, Seng Chuen
    PHARMACOECONOMICS-OPEN, 2020, 4 (02) : 235 - 247
  • [3] Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US
    Insinga, Ralph P.
    Vanness, David J.
    Feliciano, Josephine L.
    Vandormael, Kristel
    Traore, Sory
    Burke, Thomas
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (12) : 1191 - 1205
  • [4] Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients with High PD-L1 Expression in Singapore
    Tan, W. L.
    Huang, M.
    Chandwani, S.
    Hsu, T.
    Tan, S. C.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S630 - S630
  • [5] Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC
    Wan, Ning
    Zhang, Tian-tian
    Hua, Si-hua
    Lu, Zi-luo
    Ji, Bo
    Li, Li-xia
    Lu, Li-qing
    Huang, Wen-jie
    Jiang, Jie
    Li, Jian
    CANCER MEDICINE, 2020, 9 (05): : 1683 - 1693
  • [6] Cost-effectiveness modeling of dental implant 1st line strategy versus bridge
    Beresniak, A.
    Bouchard, P.
    Renouard, F.
    Bourgeois, D.
    Jeanneret, M. H.
    VALUE IN HEALTH, 2008, 11 (03) : A242 - A242
  • [7] THE COST-EFFECTIVENESS OF TREATMENT FOR ALCOHOLISM - A 1ST APPROXIMATION
    HOLDER, H
    LONGABAUGH, R
    MILLER, WR
    RUBONIS, AV
    JOURNAL OF STUDIES ON ALCOHOL, 1991, 52 (06): : 517 - 540
  • [8] Cost-effectiveness of pembrolizumab compared to ipilimumab and chemotherapy as a first line treatment for patients with advanced melanoma in Hong Kong
    Loong, H. H.
    Wong, C. K. H.
    Leung, L. K. S.
    Leung, M. T. K.
    Wang, J.
    Stevinson, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Predicting Treatment Response to 1st-line Pembrolizumab in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with High PDL1 Expression
    Janzen, I.
    Abraham, R.
    Seyyedi, S.
    Ho, C.
    Melosky, B.
    Martin, M.
    Lam, S.
    Yuan, R.
    Macaulay, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1138 - S1138
  • [10] Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong
    Herbert H. Loong
    Carlos K. H. Wong
    Linda K. S. Leung
    S. C. Tan
    Jason Jen
    Mary Y. K. Lee
    Raquel Aguiar-Ibáñez
    Jingshu Wang
    Cost Effectiveness and Resource Allocation, 18
12345